This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
by Zacks Equity Research
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.
AZNNegative Net Change NVSNegative Net Change TVTXNegative Net Change
biotechs medical pharmaceuticals
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
by Zacks Equity Research
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
NTLANegative Net Change LQDANegative Net Change KNSANegative Net Change IMCRNegative Net Change
biotechs
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
by Zacks Equity Research
Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectively.
ALKSNegative Net Change LQDANegative Net Change KNSANegative Net Change IMCRNegative Net Change
biotechs
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
by Zacks Equity Research
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change NMRAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
by Zacks Equity Research
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
BEAMNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYNegative Net Change LQDANegative Net Change MIRMNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
by Zacks Equity Research
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
RHHBYNegative Net Change JAZZNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs medical pharmaceuticals
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
by Zacks Equity Research
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
SNYNegative Net Change MGNXNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs medical
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
by Zacks Equity Research
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
INCYNegative Net Change LQDANegative Net Change MIRMNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals